Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide in Celiac Disease Undergoing Gluten Challenge
NCT04806737Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Apr 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing Teriflunomide with Placebo (2 arms). Primary endpoint: Adaptive T cell activation. Started Apr 2021; status: completed.
02
Drugs
teriflunomide
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04806737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806737.